| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | serdemetan | FIMM | pan-cancer | AAC | 0.21 | 0.2 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.2 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.21 | 0.2 |